Get the Stockscreener App
229.04
1.06%
-2.46
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $229.04, with a volume of 3.52M.
It is down -1.06% in the last 24 hours and up +9.93% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$231.50
Open:
$230.5
24h Volume:
3.52M
Relative Volume:
0.85
Market Cap:
$161.01B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
44.26
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
+4.20%
1M Performance:
+9.93%
6M Performance:
+18.20%
1Y Performance:
+8.59%
1-Day Range:
$228.36
$231.93
1-Week Range:
$219.11
$233.02
52-Week Range:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, A, IDXX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
229.04 | 161.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
690.00 | 255.13B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
393.44 | 56.71B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.97 | 48.77B | 7.23B | 1.41B | 1.09B | 4.979 |
IDXX
Idexx Laboratories Inc
|
560.36 | 44.15B | 4.45B | 1.10B | 1.06B | 13.59 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Resumed | UBS | Buy |
| Jun-11-26 | Initiated | Piper Sandler | Neutral |
| Jun-03-26 | Initiated | DZ Bank | Buy |
| Jun-02-26 | Resumed | Wolfe Research | Peer Perform |
| May-26-26 | Resumed | Citigroup | Buy |
| May-15-26 | Resumed | RBC Capital Mkts | Outperform |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science - Genetic Engineering and Biotechnology News
Danaher (DHR) Teams Up To Bring AI Into Scientific Research Workflows - Yahoo Finance
Danaher’s Stock Is Pricing in a Recovery. Can Its Earnings Deliver? - Yahoo Finance
Danaher stock: TD Cowen lifts target to USD 255.00 for Danaher stock - ad-hoc-news.de
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Zacks Investment Research
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Yahoo Finance
Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? - Zacks Investment Research
A Look at Danaher Corp (DHR) After 3.0% Gain -- GF Value $235.89 vs Price $231.50 - GuruFocus
Danaher Corp Stock (DHR) Moved Up by 3.34% on Oct 15: Drivers Behind the Movement - TradingKey
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Danaher and NVIDIA partner on AI-driven lab automation - BioXconomy
Danaher teams with NVIDIA to bring AI into scientific instruments - finchannel
Will Third-Quarter Earnings Be the Turning Point for These Two Lagging Healthcare Stocks? - NAI500
Danaher stock may move 6.2% on earnings release next week - Investing.com
For no consideration, Danaher (DHR)’s executive committee chairman waives a stock award. - Stock Titan
For no consideration, Danaher (DHR) chairman waives his stock award. - Stock Titan
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Danaher (DHR) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Danaher (DHR) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
What's Going On With Danaher Stock Wednesday?NVIDIA (NASDAQ:NVDA), Danaher (NYSE:DHR) - Benzinga
Danaher Teams Up With NVIDIA, Aims To Bring Accelerated Computing, Physical AI Into Labs - TradingView
Danaher Teams Up With NVIDIA, Aims To Bring Accelerated Computing, Physical AI Into Labs - Stocktwits
Danaher (NYSE:DHR) Sets Up for Breakout With Strong Technical Ratings - ChartMill
Danaher Corporation Announces A Collaboration with Nvidia - marketscreener.com
Danaher and NVIDIA Partner to Integrate AI Into Scientific Instruments - Unite.AI
Danaher Collaborates with NVIDIA to Advance Autonomous Science - Yahoo Finance
NVIDIA and Danaher are working to link AI with lab experiments. The initial work focuses on select instruments. - Stock Titan
Danaher Appoints Daniel Comas and Robert Hershberg to Board of Directors - citybiz
Danaher (DHR) Expands Board to 13 Members, Appoints Daniel Comas and Dr. Robert Hershberg - GuruFocus
Form 8-K DANAHER CORP /DE/ For: Oct 09 - StreetInsider
Danaher adds two directors, expands board to 13 members - Investing.com
Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors - Yahoo Finance
Danaher stock at USD 219.87 on October 9, 2026 - AD HOC NEWS
Danaher accelerates Life Sciences research with new AI-powered autonomous lab - BioSpectrum Asia
Danaher Corp. stock at EUR 196.80, market value USD 154.7 billion - AD HOC NEWS
Barclays raises target for Danaher stock to USD 255.00 - AD HOC NEWS
Did Danaher’s (DHR) New AI-Powered Autonomous Lab at Abcam Just Redefine Its Innovation Edge? - Yahoo Finance
Danaher (DHR) Stock May Be 4% Undervalued Despite AI Lab Launch - Yahoo Finance
Is Danaher (DHR) Undervalued As Its New AI Lab Pushes Faster Antibody Development? - Yahoo Finance
Danaher (DHR) Launched Its First AI Powered Autonomous Laboratory - Yahoo Finance
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab - HPCwire
Venkatesan leaves head of investment role at Danaher - Global Venturing
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - Reuters
Top Stock Reports for AMD, Palo Alto & ConocoPhillips - Zacks Investment Research
Danaher is launching an AI-powered autonomous lab for drug discovery - Quartz
Danaher stock rises 2% on AI-powered autonomous lab plans - Yahoo Finance
Danaher Corporation Announces Plans to Launch Its First Ai-Powered Autonomous Lab - marketscreener.com
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Danaher Corp Stock (DHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rainer M. Blair | Officer |
Aug 21 '26 |
Proposed Sale |
218.85 |
58,255 |
12,749,107 |
0 |
| Zerhouni Elias A. | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
46,484 |
| FILLER LINDA | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
28,010 |
| SCHWIETERS JOHN T | Former Director |
Jul 14 '26 |
Proposed Sale |
199.59 |
3,298 |
658,254 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Proposed Sale |
174.67 |
1,358 |
237,207 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
125,452 |
| SPOON ALAN G | Director |
May 01 '26 |
Sale |
174.67 |
1,358 |
237,207 |
124,094 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Option Exercise |
58.59 |
1,320 |
77,339 |
6,419 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Sale |
208.01 |
1,320 |
274,575 |
5,099 |
| Milosevich Gregory M | Officer |
Feb 19 '26 |
Proposed Sale |
208.01 |
1,320 |
274,575 |
0 |
0.93%
2.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):